Nuclear medicine capabilities.

Information Contact Center P. Hertsen Moscow Oncology Research Institute (MORI)

Information Contact Center A.Tsyb Medical Radiological Research Center (MRRC)

Federal State Budgetary Institution “National Medical Research Radiological Center” of the Ministry of Health of the Russian Federation was founded in 2014 by merging three leading research and medicine centers of the Russian Federation:

P. Hertsen Moscow Oncology Research Institute (Moscow)
A. Tsyb Medical Radiological Research Center (Obninsk, Kaluga region)
N. Lopatkin Research Institute of Urology and Interventional Radiology (Moscow).

One of the largest oncological and radiological clusters in Russia, a leading institution for radiology in Russia and a federal reference center for pathomorphological, immunohistochemical, molecular genetic & radiation research methods of diagnostics and treatment.

Since 2020 NMRRC has been the base organization in the field of oncology for the Commonwealth of Independent States.

The Center runs two federal registries: the Cancer registry and the National radiation and epidemiological registry of the Russian Federation.

The Center uses a full range of modern diagnostic methods (including molecular genetic) as well as complex and combined methods of cancer treatment.

The Center has at its disposal all types of modern linear accelerators, including gamma and cyberknives, the first and only Russian proton accelerator Prometheus, introduces advanced technologies such as: PIPAC, methods of interventional radiology, brachytherapy, treatment of radiation injuries, etc.

The Center is one of the leaders in the field of nuclear medicine, development of Russian radiopharmaceuticals and their implementation in clinical practice. Nuclear medicine technologies in combined and complex treatment provide significant / additional therapeutic benefits for both oncological and non-oncological diseases.

Nuclear medicine in National Medical Research Radiological Center of the Ministry of Health of the Russian Federation.

BRACHYTHERAPY:
- low dose rate with I-125
- high dose rate with Ir-192
- alpha with Ra-224
- ophthalmic applicators with Ru-106 and Sr-90
RADIONUCLIDE THERAPY FOR BONE METASTASES:
- Sm-153 oxabifor
- Sr-89 chloride
- Ra-223 chloride
- Re-188 phosphorene and zoleren
RADIOIODINE THERAPY:
- for thyroid cancer with I-131
- for thyrotoxicosis with I-131
Rhenium platform
RADIOEMBOLIZATION FOR LIVER TUMORS:
- microspheres with Y-90
- microspheres with Re-188
RADIONUCLIDE THERAPY FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER AND NEUROENDOCRINE TUMORS:
- Lu-177 PSMA / Ас-225 PSMA
- Lu-177 DOTA-TOC/TATE
RADIOSINOVECTOMY FOR SYNOVITIS:
- microspheres with Re-188

NUCLEAR PHARMACY. THE FUTURE OF NUCLEAR MEDICINE

The first nuclear pharmacy in Russia (the pharmacy for the synthesis of not registered in the Russian Federation radiopharmaceuticals) was set in 2021 in National Medical Research Radiological Center. Synthesized radiopharmaceuticals are successfully used for effective treatment of patients with oncological and non-oncological diseases.

The Pharmacy manufactures innovative radiopharmaceuticals based on 188Re, 177Lu and 225Ac radionuclides developed at the Center for the treatment of metastatic prostate cancer, primary and metastatic liver cancer, metastatic skeletal lesions and knee joint chronic synovitis.

It is planned to manufacture radiopharmaceuticals for the treatment of neuroendocrine malignant neoplasms, non-Hodgkin’s lymphoma, etc.

National Medical Research Radiological Centre conducts research on seven promising radiopharmaceuticals at different stages – from the development of technology, the synthesis of the radiopharmaceutical to clinical trials.

Nuclear pharmacy was opened according to GMP standards and requirements, has pharmaceutical license and is licensed for the operation of radioactive substances.

INNOVATIVE RUSSIAN RADIOPHARMACEUTICALS.

APPLICATION: castration-resistant prostate cancer treatment

CONTAINS: PSMA-617 ligand labeled with Lu-177 radionuclide.

THERAPEUTIC EFFECT: stable compound in the patient’s body, high affinity for tumor tissue, good clinical and dosimetric parameters

STATUS: Having been used in clinical practice in A. Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation since 2021.

APPLICATION: chronic synovitis of large joints (knees and elbows).

CONTAINS: protein microspheres that carry radionuclide Re – 188

THERAPEUTIC EFFECT: elimination/reduction of the inflammatory reaction that occurs in the joint as a result of exposure to Re-188 radiation

STATUS: Phase 2 clinical trials of the use of ARTROREN – MRRC in the treatment of resistant synovitis is being completed. A therapeutic effect is comparable and even superior to glucocorticosteroid therapy.

APPLICATION: inoperable primary and metastatic liver cancer treatment

CONTAINS: protein microspheres that carry radionuclide Re – 188

THERAPEUTIC EFFECT: A wire mesh is inserted into the arteries of the stomach and duodenum region to protect the vessels from possible diffusion of microspheres.

Under X-ray guidance, a catheter is placed through the skin and moved along the femoral artery into the liver vessels.

After placing the catheter in the branches of the hepatic artery feeding the tumor, microspheres containing radiopharmaceutical HEPATOREN-MRRC are introduced.

Tumor blood flow blocking and irradiating the tumor from the inside

STATUS: It is used in clinical practice – in the procedure of RADIOEMBOLIZATION for metastatic liver cancer. The procedure allows a large number of patients to take control of the tumor process in the liver. Phase 2 clinical trials is being completed

APPLICATION: metastatic castration-resistant prostate cancer treatment

CONTAINS: PSMA-617 ligand labeled with Ac-225

THERAPEUTIC EFFECT: alpha particles (Ac-225) are five times more powerful than beta particles (Y-90, Re-188, Lu-177).

STATUS: clinical trials, phase 2 – effectiveness assessment

APPLICATION: peptide receptor radionuclide therapy of metastatic neuroendocrine tumors in children and adults

CONTAINS: somatostatin receptor antagonist TOC/TATE, labeled with radionuclide Lu-177

THERAPEUTIC EFFECT: aimed at destroying distant metastases of neuroendocrine tumors

STATUS: preclinical trials have been completed.

All Re-188 based radiopharmaceuticals can be synthesized in a compact Rhenium generator. The compact size of the generator allows it to be delivered even to remote corners of Russia, and the ability to work up to 6 months provides local specialists with innovative Re-188 based radiopharmaceuticals. It can be used in any country.

Where can you receive radionuclide therapy?

Department of radionuclide therapy at A. Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation is a world leader in the treatment of cancer using radiopharmaceuticals. The method of radionuclide therapy is the flagship in domestic nuclear medicine.

The main scientific and practical task of the department is the constant improvement and introduction of new types and methods of radionuclide therapy.

You can get medical advice on this type of treatment by calling +7(484)399-31-30, or by sending your medical documents to mrrc@mrrc.obninsk.ru.

If you have a chronic disease of the knee joint, and you would like to undergo radiosynovectomy with Rhenium-188 based radiopharmaceutical at the Department of interventional radiology at A. Tsyb Medical Radiological Research Centre, send your medical documents and all contact details to mrrc@mrrc.obninsk.ru with the subject “Radiosynovectomy”.